Filing Summary: Vital Therapies, Inc. — Form 10-Q for Q2 2016
Entity note: The request metadata identifies IMMUNIC, INC., but the supplied filing is for Vital Therapies, Inc. This summary reflects the filing text and does not establish that it belongs to IMMUNIC.
Business context and reporting period
The unaudited report covers the three and six months ended June 30, 2016, with comparisons to the corresponding 2015 periods. Vital Therapies was a clinical-stage biotherapeutic company developing the ELAD System, an extracorporeal cell-based treatment for acute liver failure. It had no revenue from planned principal operations and relied on external financing.
After its VTI-208 Phase 3 trial failed to meet primary or secondary endpoints in 2015, the company discontinued VTI-210 and VTI-212 and started VTL-308, a new Phase 3 trial focused on severe acute alcoholic hepatitis (sAAH). As of July 31, 2016, eight subjects had enrolled and 23 sites were open.
Key financial metrics
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $6.858 million | $11.545 million | $13.715 million | $23.299 million |
| General and administrative expense | $2.688 million | $3.533 million | $5.487 million | $6.597 million |
| Total operating expenses | $9.546 million | $15.078 million | $19.202 million | $29.896 million |
| Net loss | $9.468 million | $15.106 million | $19.057 million | $29.864 million |
| Net loss per share, basic and diluted | $0.30 | $0.63 | $0.62 | $1.25 |
| Cash used in operating activities | Not presented by quarter | Not presented by quarter | $18.783 million | $28.623 million |
At June 30, 2016, cash and cash equivalents were $73.598 million, restricted cash was $0.239 million, total current assets were $75.436 million, and total assets were $78.632 million. Current liabilities were $4.473 million; long-term liabilities were $0.012 million. Stockholders’ equity was $74.147 million. The balance sheet reports no borrowings or other debt balance.
For the first six months of 2016, investing activities provided $0.131 million and financing activities provided $8.835 million, including $8.823 million net proceeds from common-stock issuance. Cash and cash equivalents fell by $9.818 million from year-end 2015. The company reported an accumulated deficit of $221.913 million. Profit margins are not meaningful because the company reported no revenue.
Material changes versus prior comparable periods
- Operating expenses declined 37% in Q2 and 36% in the first half versus 2015; net loss narrowed to $9.468 million for Q2 and $19.057 million for the first half.
- R&D expense fell 41% in both comparisons, primarily because fewer clinical trials were active, associated trial and manufacturing costs were lower, and the company reduced staff in late 2015. VTL-308 site-opening and enrollment costs continued in 2016.
- G&A expense fell 24% in Q2 and 17% in the first half, mainly reflecting workforce reductions and lower travel, consulting, and compensation costs.
- Operating cash use improved by $9.840 million year over year for the first half. Capital expenditures also decreased, from $1.980 million to $0.165 million.
- ATM stock sales raised $9.2 million gross and $8.8 million net during the first half; 1.1 million shares had been sold at a weighted-average price of $8.71. Shares issued and outstanding rose to 31,539,111 at June 30, from 30,473,083 at December 31, 2015.
Outlook, risks, contingencies, and unusual items
- Management estimated that June 30 cash would fund operations into the first quarter of 2018, assuming limited BLA-related work and no significant commercial buildout. It anticipated raising additional funds before releasing VTL-308 topline data, then expected in mid-2018. These are forward-looking estimates; the company had no committed external funding source.
- Management expected R&D costs to increase during the remainder of 2016, depending on VTL-308 enrollment; G&A could also rise, partly due to securities-litigation costs.
- VTL-308 was designed using analyses of VTI-208 results, including subgroup trends, after VTI-208 failed its primary and secondary endpoints. The new trial’s assumptions and ability to show a statistically significant survival benefit remain uncertain; regulators could require another pivotal study even if it succeeds.
- A putative securities class action was consolidated and an amended complaint filed, alleging investor misrepresentation concerning the clinical trials. The company moved to dismiss, intended to defend the case, and said it could not estimate a loss range; no liability was accrued. A hearing was scheduled for September 1, 2016.
- Key risks include clinical-trial failure or delay, enrollment challenges, regulatory approval and manufacturing requirements, dependence on a single product candidate, supplier concentration, and the need for additional capital. Equity financing could dilute shareholders; financing may not be available on acceptable terms.
- The company reported effective disclosure controls as of June 30, 2016, and no material change in internal control over financial reporting during the quarter. It also disclosed a prior material weakness in internal controls, stating remediation efforts had been completed while noting future deficiencies could still arise.
Most important facts for investors to verify
- Confirm that the filing is for Vital Therapies, Inc., not the company named in the request metadata.
- Track VTL-308 site openings, enrollment, trial design, event accrual, and timing of topline data; verify any subsequent regulatory or clinical updates.
- Monitor cash burn and financing activity against management’s runway estimate into Q1 2018, including the dilution and availability of remaining shelf and ATM capacity.
- Review the status and potential financial impact of the securities litigation; the filing provides no estimable loss range.
- Assess whether reduced spending reflects sustainable efficiencies or chiefly the discontinued trials and workforce reduction, and whether expected trial-cost increases alter the funding outlook.